NCT00401726View on ClinicalTrials.gov

Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program

PHASE4CompletedINTERVENTIONAL

Enrollment

537

Participants

Timeline

Start Date

June 30, 2006

Study Completion Date

October 31, 2007

Conditions

Depressive Disorder, Major

Interventions

DRUG

Venlafaxine ER

BEHAVIORAL

Dialogues Time to Talk Program

Trial Locations (44)

18104

Allentown

18940

Newtown

19606

Reading

19805

Wilmington

25301

Charleston

28209

Charlotte

28262

Charlotte

29621

Anderson

29651

Greer

30120

Cartersville

30165

Rome

30308

Atlanta

33781

Pinellas Park

34471

Ocala

34996

Stuart

35216

Birmingham

35235

Birmingham

37620

Bristol

43212

Columbus

44260

Mogadore

45040

Mason

45236

Cincinnati

45429

Kettering

47630

Newburgh

49009

Kalamazoo

49616

Benzonia

49643

Interlochen

50702

Waterloo

63017

Chesterfield

68134

Omaha

70006

Metairie

72211

Little Rock

75093

Plano

75235

Dallas

76135

Fort Worth

78229

San Antonio

83404

Idaho Falls

84107

Salt Lake City

85206

Mesa

89146

Las Vegas

95128

San Jose

06001

Avon

06416

Cromwell

02886

Warwick

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00401726 - Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program | Biotech Hunter | Biotech Hunter